A comparative study of milnacipran and imipramine in the treatment of major depressive disorder
Lopez-Ibor JJ, Conesa A;
Spanish Milnacipran/Imipramine Study.
Hospital Ramon Y Cajal, Madrid, Spain.
Curr Med Res Opin. 2004 Jun;20(6):855-60


The antidepressant efficacy and safety of milnacipran, a dual action antidepressant drug which inhibits the reuptake of serotonin and noradrenaline, was compared with that of the tricyclic antidepressant, imipramine, in a multi-centre, double-blind, randomised, parallel group, comparative trial in 5 hospital centres in Spain. One hundred patients hospitalised with a diagnosis of major depressive disorder according to the Diagnostic and Statistical Manual of the American Psychiatry Association (third revision), with a minimum score of 25 on the Montgomery and Asberg Depression Rating Scale were treated for 6 weeks with milnacipran (100 mg/day) or imipramine (150 mg/day). Both treatments showed similar efficacy in reducing depressive symptoms. The frequency of most adverse events in the milnacipran-treated patients was lower than that observed in the imipramine group, particularly those related to anticholinergic symptoms. Dysuria and shivering, however, were more common with milnacipran. The results of this study support others which have demonstrated that milnacipran has equivalent efficacy but superior tolerability to a tricyclic antidepressant such as imipramine.
Milnacipran (Ixel) : structure
Milnacipran versus fluvoxamine
Milnacipran and the dopamine system
Milnacipran for post-stroke depression
Milnacipran for depression after brain injury
Milnacipran (Ixel): dosage and antidepressant response
Cabergoline plus milnacipram (Ixel) for refractory depression

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family